DDInter638 DDInter1763
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling. Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes v
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Enalapril {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Enalapril {u} (Compound) downregulates {v} (Gene) CTNND1
CTNND1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Enalapril {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Enalapril {u} (Compound) downregulates {v} (Gene) ATP6V1D
ATP6V1D {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Enalapril {u} (Compound) causes {v} (Side Effect) Pharyngitis
Pharyngitis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Enalapril {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Enalapril {u} (Compound) downregulates {v} (Gene) CTNND1
CTNND1 {u} (Gene) is regulated by {v} (Gene) MKNK1
MKNK1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Enalapril {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Enalapril (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Enalapril (Compound) downregulates CTNND1 (Gene) and CTNND1 (Gene) is upregulated by Temsirolimus (Compound)
Enalapril (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Temsirolimus (Compound)
Enalapril (Compound) downregulates ATP6V1D (Gene) and ATP6V1D (Gene) is downregulated by Temsirolimus (Compound)
Enalapril (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Temsirolimus (Compound)
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Enalapril (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Enalapril (Compound) downregulates CTNND1 (Gene) and CTNND1 (Gene) is regulated by MKNK1 (Gene) and MKNK1 (Gene) is upregulated by Temsirolimus (Compound)
Enalapril (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)